Molecular phenotypes stratify small cell lung cancer for targeted therapy and immunotherapy.
Summary
This study identified three distinct molecular phenotypes of small cell lung cancer (SCLC): proliferative, iNotch, and infiltrated, characterized by high proliferation, inhibitory Notch signaling, and immune-rich microenvironments, respectively. These phenotypes were reproducible across multiple independent cohorts. Further analysis revealed that a subset of patients within the infiltrated phenotype, exhibiting high ANXA1 expression, resisted immune checkpoint inhibitors (ICIs) due to M2 macrophage polarization and CD8+ T cell suppression. Only ANXA1Low infiltrated patients derived significant benefit from chemotherapy combined with ICIs. These findings offer new strategies to enhance immunotherapy efficacy in SCLC.
Analysis
🔴 CLINICAL: This study identifies a predictive biomarker (ANXA1 expression within the infiltrated phenotype) for ICI response in extensive-stage SCLC patients. ANXA1Low infiltrated patients significantly benefit from chemotherapy-ICI combination, while ANXA1High infiltrated patients are resistant. These findings, based on a cohort of 41 newly collected patients and a public dataset, could justify phase II clinical trials to validate ANXA1 expression as a patient stratification tool, enabling better selection of immunotherapy candidates and potentially developing strategies to overcome resistance in ANXA1High patients. Clinical impact could be seen within 3-5 years. 🟢 BIOMOL: The discovery of three distinct SCLC molecular phenotypes (proliferative, iNotch, infiltrated) is a major advance in understanding the heterogeneity of this disease. The use of bulk and single-cell RNA sequencing (scRNA-seq) allowed for the characterization of these phenotypes and the deciphering of tumor microenvironment interactions. The identification of ANXA1's role in M2 macrophage polarization and CD8+ T cell suppression as a mechanism of ICI resistance is a key translational discovery. This paves the way for developing diagnostic tests based on ANXA1 expression to guide therapeutic decisions and new targets to overcome resistance. 🔵 BIOINFO: The study utilized consensus clustering on bulk transcriptomic data to robustly identify SCLC phenotypes, demonstrating their reproducibility across three independent datasets. Intercellular communication analysis from scRNA-seq data represents an advanced bioinformatic application to understand complex interactions within the tumor microenvironment. These bioinformatic approaches are crucial for biomarker discovery and patient stratification, and could be integrated into clinical analysis pipelines to refine SCLC diagnosis and prognosis.